Research output per year
Research output per year
Fingerprint
Dive into the research topics where Jorge Eduardo Cortes is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
-
THERAPY OF CML
Cortes, J. E., Kurzrock, R., Ming-Sheng, L., Reading, C., Emerson, S., Liang, J., Deisseroth, A., Feinberg, A., Siciliano, M., Kantarjian, H., Talpaz, M., Andreeff, M., Kornblau, S., Thall, P., Issa, J. P., Estrov, Z., Arlinghaus, R. B., Deininger, M., Champlin, R., Shpall, E., Austin, D., Claxton, D., Belmont, J., Reisner, Y. & Issa, K.
Project: Research project
Research output
-
Asciminib for the treatment of patients with chronic myeloid leukemia
Cortes, J. & Whitaker, C. F., Apr 2021, In: Clinical Advances in Hematology and Oncology. 19, 4, p. 207-208 2 p.Research output: Contribution to journal › Article › peer-review
-
Assessment of Outcomes after Stopping Tyrosine Kinase Inhibitors among Patients with Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial
Atallah, E., Schiffer, C. A., Radich, J. P., Weinfurt, K. P., Zhang, M. J., Pinilla-Ibarz, J., Kota, V., Larson, R. A., Moore, J. O., Mauro, M. J., Deininger, M. W. N., Thompson, J. E., Oehler, V. G., Wadleigh, M., Shah, N. P., Ritchie, E. K., Silver, R. T., Cortes, J., Lin, L., Visotcky, A. & 5 others, , Jan 2021, In: JAMA Oncology. 7, 1, p. 42-50 9 p., e205671.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics (Nature Communications, (2020), 11, 1, (5327), 10.1038/s41467-020-19119-8)
Morita, K., Wang, F., Jahn, K., Hu, T., Tanaka, T., Sasaki, Y., Kuipers, J., Loghavi, S., Wang, S. A., Yan, Y., Furudate, K., Matthews, J., Little, L., Gumbs, C., Zhang, J., Song, X., Thompson, E., Patel, K. P., Bueso-Ramos, C. E., DiNardo, C. D. & 13 others, , Dec 2021, In: Nature communications. 12, 1, 2823.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study
Borthakur, G., Ofran, Y., Tallman, M. S., Foran, J., Uy, G. L., DiPersio, J. F., Showel, M. M., Shimoni, A., Nagler, A., Rowe, J. M., Altman, J. K., Abraham, M., Peled, A., Shaw, S., Bohana-Kashtan, O., Sorani, E., Pereg, Y., Foley-Comer, A., Oberkovitz, G., Lustig, T. M. & 10 others, , Apr 15 2021, In: Cancer. 127, 8, p. 1246-1259 14 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Heuser, M., Smith, B. D., Fiedler, W., Sekeres, M. A., Montesinos, P., Leber, B., Merchant, A., Papayannidis, C., Pérez-Simón, J. A., Hoang, C. J., O’Brien, T., Ma, W. W., Zeremski, M., O’Connell, A., Chan, G. & Cortes, J. E., May 2021, In: Annals of Hematology. 100, 5, p. 1181-1194 14 p.Research output: Contribution to journal › Article › peer-review
Open Access